Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (357)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
28
2022
381
3.980
 Why?
Everolimus
10
2016
61
2.570
 Why?
Health Resources
8
2022
120
2.410
 Why?
Cost of Illness
12
2022
254
2.190
 Why?
Receptor, ErbB-2
9
2016
300
1.600
 Why?
Breast Neoplasms
12
2016
1846
1.540
 Why?
Medication Adherence
6
2016
531
1.280
 Why?
Hyperkalemia
2
2020
26
1.260
 Why?
Receptors, Estrogen
3
2015
371
1.240
 Why?
Receptors, Antigen, T-Cell
4
2021
615
1.240
 Why?
Immunotherapy, Adoptive
2
2020
184
1.210
 Why?
Health Expenditures
6
2020
172
1.090
 Why?
Practice Patterns, Physicians'
4
2016
1175
1.070
 Why?
Health Services
6
2016
103
0.980
 Why?
United States
39
2022
12137
0.950
 Why?
Receptors, Progesterone
2
2015
319
0.870
 Why?
Models, Economic
2
2020
48
0.850
 Why?
Hepatitis C, Chronic
2
2015
150
0.850
 Why?
Middle Aged
52
2020
26605
0.840
 Why?
Antifungal Agents
4
2017
128
0.810
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
97
0.800
 Why?
Antineoplastic Agents
9
2016
1875
0.790
 Why?
Aged
38
2022
18969
0.780
 Why?
Retrospective Studies
31
2022
12521
0.770
 Why?
Hospital Costs
3
2020
104
0.740
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2016
1356
0.720
 Why?
Gout
2
2012
36
0.720
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
256
0.700
 Why?
Female
63
2021
59324
0.680
 Why?
Nocturia
1
2019
7
0.670
 Why?
Hospitalization
13
2021
1762
0.660
 Why?
Proportional Hazards Models
12
2017
1078
0.640
 Why?
Kaplan-Meier Estimate
10
2017
813
0.630
 Why?
Cost-Benefit Analysis
12
2022
544
0.620
 Why?
Depressive Disorder, Major
3
2011
301
0.620
 Why?
Humans
80
2022
114045
0.610
 Why?
Nutrition Surveys
1
2019
225
0.600
 Why?
Male
53
2021
55396
0.600
 Why?
Proline
2
2015
72
0.590
 Why?
Candida
2
2017
32
0.590
 Why?
Adult
41
2022
30375
0.580
 Why?
Medicare
7
2022
661
0.570
 Why?
Prevalence
10
2020
2247
0.570
 Why?
Fluconazole
1
2017
16
0.570
 Why?
Candidemia
1
2017
7
0.560
 Why?
Myocardial Perfusion Imaging
1
2017
34
0.560
 Why?
Cardiologists
1
2017
40
0.550
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
75
0.550
 Why?
Fees, Pharmaceutical
3
2016
13
0.540
 Why?
Oligopeptides
2
2015
234
0.540
 Why?
Thrombolytic Therapy
1
2017
117
0.530
 Why?
Renal Insufficiency, Chronic
2
2020
486
0.530
 Why?
Insurance Claim Review
8
2017
68
0.520
 Why?
Antirheumatic Agents
2
2016
255
0.520
 Why?
Hypoglycemic Agents
2
2015
1011
0.510
 Why?
Biological Therapy
1
2016
26
0.510
 Why?
Citalopram
3
2011
28
0.500
 Why?
Tissue Plasminogen Activator
1
2017
204
0.500
 Why?
Databases, Factual
8
2016
1125
0.500
 Why?
Drug Eruptions
1
2015
26
0.490
 Why?
Psoriasis
3
2012
80
0.480
 Why?
Fibrinolytic Agents
1
2017
231
0.480
 Why?
Comparative Effectiveness Research
2
2012
131
0.470
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
296
0.470
 Why?
Liver Neoplasms
2
2015
504
0.470
 Why?
Diphosphonates
2
2012
51
0.460
 Why?
Delivery of Health Care
2
2019
828
0.460
 Why?
Physicians, Primary Care
1
2017
222
0.450
 Why?
Anemia
1
2015
143
0.450
 Why?
Brain Ischemia
1
2017
297
0.450
 Why?
Imidazoles
2
2012
203
0.440
 Why?
Antiviral Agents
2
2015
642
0.420
 Why?
Dextroamphetamine
1
2012
3
0.410
 Why?
Aged, 80 and over
11
2020
6306
0.400
 Why?
Referral and Consultation
1
2017
632
0.400
 Why?
Methylphenidate
1
2012
36
0.400
 Why?
Hypertension
4
2018
1052
0.400
 Why?
Drug Delivery Systems
1
2015
295
0.390
 Why?
Pulmonary Embolism
1
2014
180
0.390
 Why?
Drug Costs
6
2015
92
0.380
 Why?
Schizophrenia
2
2006
412
0.380
 Why?
Neoplasm Metastasis
6
2016
521
0.380
 Why?
Fumarates
1
2011
10
0.370
 Why?
Drugs, Generic
1
2011
18
0.370
 Why?
Drug Substitution
1
2011
46
0.360
 Why?
Postmenopause
4
2016
301
0.360
 Why?
Central Nervous System Stimulants
1
2012
140
0.360
 Why?
Bone Diseases
1
2011
57
0.350
 Why?
Venous Thromboembolism
1
2014
230
0.350
 Why?
Stroke
2
2017
1019
0.350
 Why?
Angiotensin Receptor Antagonists
1
2011
76
0.350
 Why?
Arthritis, Rheumatoid
2
2016
1002
0.350
 Why?
Amides
1
2011
87
0.350
 Why?
Diabetes Mellitus, Type 2
2
2015
2087
0.340
 Why?
Diabetes Mellitus
1
2018
898
0.340
 Why?
Multiple Myeloma
1
2011
98
0.340
 Why?
Anticoagulants
1
2014
547
0.340
 Why?
Crohn Disease
5
2012
196
0.330
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
180
0.330
 Why?
Insurance, Health
3
2011
243
0.330
 Why?
Antibodies, Monoclonal
6
2011
1257
0.320
 Why?
Sick Leave
2
2007
13
0.320
 Why?
Risk Factors
12
2017
8614
0.320
 Why?
Hyperuricemia
1
2009
43
0.320
 Why?
Quality of Life
8
2021
2343
0.320
 Why?
Heart Failure
2
2020
1958
0.320
 Why?
Patient Acceptance of Health Care
7
2021
675
0.310
 Why?
Disease-Free Survival
5
2016
618
0.310
 Why?
Antineoplastic Agents, Hormonal
3
2016
138
0.310
 Why?
Attention Deficit Disorder with Hyperactivity
1
2012
363
0.310
 Why?
Costs and Cost Analysis
7
2019
196
0.310
 Why?
Absenteeism
2
2005
40
0.300
 Why?
Comorbidity
8
2014
1447
0.300
 Why?
Uric Acid
1
2009
148
0.300
 Why?
Neoplasm Recurrence, Local
2
2015
850
0.300
 Why?
Insulin
2
2015
2080
0.290
 Why?
Head and Neck Neoplasms
1
2012
427
0.290
 Why?
Physicians
1
2015
765
0.290
 Why?
Insurance Claim Reporting
2
2007
21
0.290
 Why?
Hypoglycemia
1
2012
386
0.280
 Why?
Young Adult
12
2020
10444
0.270
 Why?
Triazoles
3
2016
125
0.270
 Why?
Health Status Indicators
1
2007
155
0.270
 Why?
Pentosan Sulfuric Polyester
1
2006
1
0.260
 Why?
Economics, Pharmaceutical
1
2006
10
0.260
 Why?
Cystitis, Interstitial
1
2006
16
0.260
 Why?
Drug Resistance, Fungal
2
2017
9
0.260
 Why?
Endometriosis
2
2017
40
0.250
 Why?
Prostatic Neoplasms
2
2012
913
0.240
 Why?
Urinary Incontinence
1
2005
56
0.240
 Why?
Immunoglobulin G
1
2008
766
0.240
 Why?
Recurrence
3
2020
925
0.230
 Why?
Treatment Outcome
12
2017
9049
0.230
 Why?
Psychotic Disorders
1
2005
114
0.220
 Why?
Antibodies, Monoclonal, Humanized
7
2012
660
0.220
 Why?
Drug Therapy, Combination
4
2015
949
0.210
 Why?
Population Surveillance
1
2005
385
0.200
 Why?
Adolescent
17
2017
17800
0.190
 Why?
Anti-Inflammatory Agents
3
2011
445
0.190
 Why?
Biological Products
2
2016
166
0.190
 Why?
Bone Density Conservation Agents
2
2012
62
0.190
 Why?
Gastritis
1
2022
84
0.190
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
2
0.190
 Why?
Enteritis
1
2022
82
0.190
 Why?
Adenocarcinoma
1
2007
787
0.180
 Why?
Gout Suppressants
2
2012
20
0.180
 Why?
Tumor Necrosis Factor-alpha
4
2009
1128
0.180
 Why?
Hemophilia B
1
2021
36
0.180
 Why?
Hemophilia A
1
2021
67
0.180
 Why?
Eosinophilia
1
2022
186
0.170
 Why?
Genetic Therapy
1
2021
256
0.170
 Why?
National Health Programs
1
2019
20
0.170
 Why?
Voriconazole
2
2016
24
0.170
 Why?
Technology Assessment, Biomedical
1
2019
29
0.170
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
500
0.170
 Why?
Regression Analysis
4
2012
945
0.170
 Why?
Aging
1
2009
1611
0.160
 Why?
Myelodysplastic Syndromes
1
2021
119
0.160
 Why?
Microbial Sensitivity Tests
2
2017
300
0.160
 Why?
Nitriles
2
2016
149
0.150
 Why?
Treatment Failure
2
2017
330
0.150
 Why?
Overweight
1
2022
473
0.150
 Why?
Vital Capacity
2
2015
254
0.150
 Why?
Emergency Service, Hospital
3
2014
1815
0.150
 Why?
Polystyrenes
1
2018
36
0.150
 Why?
Mental Disorders
1
2005
889
0.140
 Why?
Potassium
1
2018
127
0.140
 Why?
4-Aminopyridine
1
2017
21
0.140
 Why?
Antihypertensive Agents
2
2011
428
0.140
 Why?
Retreatment
1
2017
67
0.140
 Why?
Administration, Intravenous
1
2017
122
0.140
 Why?
Patient Compliance
2
2011
524
0.140
 Why?
Aspergillosis
1
2016
23
0.140
 Why?
Consumer Behavior
1
2017
65
0.140
 Why?
Abiraterone Acetate
1
2016
14
0.140
 Why?
Hysterectomy
1
2017
105
0.130
 Why?
Chronic Disease
3
2014
1577
0.130
 Why?
Administrative Claims, Healthcare
1
2016
22
0.130
 Why?
Health Care Rationing
1
2016
45
0.130
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
40
0.130
 Why?
Aromatase Inhibitors
1
2016
49
0.130
 Why?
Time-to-Treatment
1
2017
146
0.130
 Why?
Ambulatory Care
3
2015
479
0.130
 Why?
Capecitabine
1
2016
45
0.130
 Why?
Clinical Protocols
1
2017
232
0.130
 Why?
Patient Admission
1
2017
175
0.130
 Why?
Prednisone
1
2016
229
0.130
 Why?
Disability Evaluation
1
2017
271
0.130
 Why?
Waiting Lists
1
2017
206
0.120
 Why?
Logistic Models
2
2014
1829
0.120
 Why?
International Classification of Diseases
1
2016
116
0.120
 Why?
Cross-Sectional Studies
3
2019
4402
0.120
 Why?
Ki-1 Antigen
1
2015
4
0.120
 Why?
Androstadienes
1
2015
97
0.120
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
16
0.120
 Why?
Drug Interactions
1
2016
337
0.120
 Why?
California
2
2006
351
0.120
 Why?
Follow-Up Studies
5
2015
4392
0.120
 Why?
Leukemia, Myeloid, Acute
1
2021
533
0.120
 Why?
Ribavirin
1
2015
89
0.120
 Why?
Drug Administration Schedule
3
2011
714
0.110
 Why?
Recombinant Proteins
1
2017
1228
0.110
 Why?
International Normalized Ratio
1
2014
42
0.110
 Why?
Heparin, Low-Molecular-Weight
1
2014
26
0.110
 Why?
Amphotericin B
1
2014
28
0.110
 Why?
Insurance, Health, Reimbursement
1
2014
88
0.110
 Why?
Pulmonary Disease, Chronic Obstructive
2
2011
907
0.110
 Why?
Immunoconjugates
1
2015
87
0.110
 Why?
Constipation
1
2014
75
0.110
 Why?
Drug Prescriptions
1
2015
237
0.110
 Why?
Recovery of Function
1
2017
573
0.110
 Why?
China
1
2014
161
0.110
 Why?
ErbB Receptors
2
2016
554
0.110
 Why?
Mycoses
1
2014
66
0.110
 Why?
Models, Theoretical
1
2017
513
0.110
 Why?
Morpholines
1
2014
102
0.110
 Why?
Pyridines
1
2016
419
0.110
 Why?
Thiophenes
1
2014
108
0.110
 Why?
Drug Combinations
2
2011
286
0.110
 Why?
Hodgkin Disease
1
2015
121
0.110
 Why?
Warfarin
1
2014
136
0.110
 Why?
Laparoscopy
1
2017
395
0.100
 Why?
Budgets
1
2012
14
0.100
 Why?
Multivariate Analysis
4
2015
1422
0.100
 Why?
Allopurinol
1
2012
53
0.100
 Why?
Health Status
2
2008
716
0.100
 Why?
Gastrointestinal Diseases
1
2014
182
0.100
 Why?
Adalimumab
5
2011
44
0.100
 Why?
Lisdexamfetamine Dimesylate
1
2012
4
0.100
 Why?
Multiple Sclerosis
1
2017
372
0.100
 Why?
Estradiol
1
2015
450
0.100
 Why?
Neoplasm Staging
1
2015
1162
0.100
 Why?
Rivaroxaban
1
2014
211
0.100
 Why?
Immunocompromised Host
1
2014
192
0.100
 Why?
Databases as Topic
2
2009
63
0.100
 Why?
Patient Readmission
1
2017
607
0.100
 Why?
Medicaid
2
2006
404
0.100
 Why?
Sulfonylurea Compounds
1
2012
44
0.100
 Why?
Communication
1
2017
734
0.100
 Why?
Sirolimus
1
2012
181
0.090
 Why?
Models, Statistical
2
2012
595
0.090
 Why?
Fractures, Spontaneous
1
2011
13
0.090
 Why?
Spinal Cord Compression
1
2011
17
0.090
 Why?
Hypercalcemia
1
2011
19
0.090
 Why?
Cost Sharing
1
2011
14
0.090
 Why?
Efficiency
2
2011
84
0.090
 Why?
Japan
2
2021
85
0.090
 Why?
Bone Diseases, Metabolic
1
2011
53
0.090
 Why?
Bone Neoplasms
1
2012
191
0.090
 Why?
Antidepressive Agents, Second-Generation
1
2010
38
0.090
 Why?
Severity of Illness Index
4
2012
2537
0.090
 Why?
Surveys and Questionnaires
3
2021
4595
0.090
 Why?
Obesity
1
2022
2505
0.090
 Why?
Bronchodilator Agents
1
2011
239
0.080
 Why?
Angiogenesis Inhibitors
1
2011
213
0.080
 Why?
Administration, Oral
1
2012
725
0.080
 Why?
Linear Models
1
2012
768
0.080
 Why?
Antidepressive Agents
1
2011
195
0.080
 Why?
Case-Control Studies
2
2014
3003
0.080
 Why?
Gastrointestinal Agents
1
2009
60
0.080
 Why?
Time Factors
2
2017
6077
0.080
 Why?
Etanercept
1
2008
51
0.080
 Why?
Blood Chemical Analysis
1
2009
90
0.080
 Why?
Age Distribution
3
2015
341
0.080
 Why?
Receptors, Tumor Necrosis Factor
1
2008
140
0.080
 Why?
Employment
2
2007
137
0.070
 Why?
Clinical Trials as Topic
1
2012
926
0.070
 Why?
Digestive System Surgical Procedures
1
2008
91
0.070
 Why?
Quality-Adjusted Life Years
2
2022
103
0.070
 Why?
Child
4
2020
18401
0.070
 Why?
Veterans Disability Claims
1
2006
1
0.070
 Why?
Health Benefit Plans, Employee
1
2006
20
0.070
 Why?
Private Sector
1
2006
51
0.070
 Why?
Coronary Disease
1
2008
348
0.060
 Why?
Cohort Studies
2
2012
4883
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Metabolic Diseases
1
2007
98
0.060
 Why?
Ischemic Attack, Transient
1
2006
62
0.060
 Why?
Hallucinations
1
2005
30
0.060
 Why?
Colorectal Neoplasms
1
2011
592
0.060
 Why?
Area Under Curve
1
2005
273
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
959
0.060
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
230
0.060
 Why?
Metabolic Syndrome
1
2007
320
0.060
 Why?
Asthma
2
2007
2021
0.060
 Why?
Age Factors
2
2015
2885
0.060
 Why?
Adrenal Cortex Hormones
1
2007
493
0.060
 Why?
Data Collection
1
2006
618
0.050
 Why?
Lung
1
2015
3521
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
481
0.050
 Why?
Drug Resistance, Neoplasm
1
2007
636
0.050
 Why?
Interviews as Topic
1
2005
575
0.050
 Why?
Anti-Asthmatic Agents
1
2006
348
0.050
 Why?
Health Policy
1
2005
330
0.050
 Why?
Glucagon-Like Peptides
1
2022
22
0.050
 Why?
Mental Health Services
1
2005
316
0.050
 Why?
Double-Blind Method
3
2011
1656
0.050
 Why?
Incidence
1
2006
2314
0.040
 Why?
Asia
1
2019
53
0.040
 Why?
Disease Progression
2
2015
2371
0.040
 Why?
Administration, Inhalation
2
2011
637
0.040
 Why?
Potassium Channel Blockers
1
2017
29
0.040
 Why?
Disease Management
2
2015
556
0.040
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Delayed-Action Preparations
1
2017
158
0.030
 Why?
Itraconazole
1
2016
7
0.030
 Why?
B-Lymphocytes
1
2020
762
0.030
 Why?
Cardiovascular Diseases
1
2007
1726
0.030
 Why?
Utilization Review
1
2014
34
0.030
 Why?
Early Diagnosis
1
2015
217
0.030
 Why?
Dose-Response Relationship, Drug
2
2009
1836
0.030
 Why?
Forced Expiratory Volume
1
2015
471
0.030
 Why?
Hypothyroidism
1
2014
65
0.030
 Why?
Aspergillus
1
2014
16
0.030
 Why?
Cryptococcus
1
2014
7
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
53
0.030
 Why?
Peripheral Vascular Diseases
1
2014
97
0.030
 Why?
Mood Disorders
1
2014
112
0.030
 Why?
Acute Disease
1
2015
907
0.030
 Why?
Biopsy
1
2015
1024
0.020
 Why?
Molecular Targeted Therapy
1
2015
347
0.020
 Why?
Risk
1
2014
810
0.020
 Why?
Matched-Pair Analysis
1
2011
33
0.020
 Why?
Critical Care
1
2015
472
0.020
 Why?
Nervous System Diseases
1
2014
254
0.020
 Why?
Length of Stay
1
2015
957
0.020
 Why?
Cetuximab
1
2011
90
0.020
 Why?
Bevacizumab
1
2011
114
0.020
 Why?
Tablets
1
2010
36
0.020
 Why?
State Medicine
1
2009
18
0.020
 Why?
Sex Factors
1
2015
1706
0.020
 Why?
Epidemiologic Methods
1
2009
72
0.020
 Why?
Remission Induction
1
2009
233
0.020
 Why?
United Kingdom
1
2009
226
0.020
 Why?
Insurance Coverage
1
2010
199
0.020
 Why?
Injections, Subcutaneous
1
2009
134
0.020
 Why?
Maximum Tolerated Dose
1
2009
183
0.020
 Why?
Odds Ratio
1
2011
951
0.020
 Why?
Europe
1
2009
332
0.020
 Why?
Probability
1
2009
286
0.020
 Why?
Statistics, Nonparametric
1
2009
384
0.020
 Why?
Longitudinal Studies
1
2014
2384
0.020
 Why?
Canada
1
2009
320
0.020
 Why?
Prognosis
1
2015
3315
0.020
 Why?
Confidence Intervals
1
2008
302
0.020
 Why?
Reference Values
1
2009
739
0.020
 Why?
Sex Distribution
1
2008
336
0.020
 Why?
Randomized Controlled Trials as Topic
1
2012
1204
0.020
 Why?
Models, Biological
1
2014
1611
0.020
 Why?
Tomography, X-Ray Computed
1
2015
2272
0.020
 Why?
Health Status Disparities
1
2008
200
0.020
 Why?
Infant
2
2007
7943
0.010
 Why?
Child, Preschool
2
2007
9114
0.010
 Why?
Emergency Medical Services
1
2007
581
0.010
 Why?
Risk Assessment
1
2009
2958
0.010
 Why?
Body Mass Index
1
2007
1957
0.010
 Why?
Infant, Newborn
1
2006
5038
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (357) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)